PODD logo

Insulet (PODD) Company Overview

Profile

Full Name:

Insulet Corporation

Sector:

Healthcare

Country:

United States

IPO:

May 15, 2007

Indexes:

Description:

Insulet Corporation is a company that designs, manufactures, and commercializes medical devices for insulin therapy. Founded in 2000, the company's headquarters is located in Acton, Massachusetts. Insulet's focus is on the development, production, and sale of its patented Omnipod system - an innovative, discreet, and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod system provides continuous insulin delivery at a predetermined rate, eliminating the need for individual insulin injections. Additionally, insulin delivery can be adjusted with the push of a button to adapt to unexpected changes in a patient's daily schedule.

Key Details

Price

$268.00

Annual Revenue

$2.07 B(+22.07% YoY)

Annual EPS

$5.78(+96.60% YoY)

Beta

0.86

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 20, 2025

Recent annual earnings:

Feb 20, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 21, 25 Wells Fargo
Overweight
Feb 21, 25 Stifel
Hold
Feb 21, 25 Raymond James
Outperform
Feb 21, 25 Piper Sandler
Overweight
Feb 21, 25 Citigroup
Buy
Feb 21, 25 Canaccord Genuity
Buy
Jan 3, 25 TD Cowen
Buy
Dec 12, 24 JP Morgan
Overweight
Dec 11, 24 Wells Fargo
Overweight
Dec 11, 24 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Insulet?
  • Does Insulet pay dividends?
  • What sector is Insulet in?
  • What industry is Insulet in?
  • What country is Insulet based in?
  • When did Insulet go public?
  • Is Insulet in the S&P 500?
  • Is Insulet in the NASDAQ 100?
  • Is Insulet in the Dow Jones?
  • When was Insulet's last earnings report?
  • When does Insulet report earnings?
  • Should I buy Insulet stock now?

What is the ticker symbol for Insulet?

The ticker symbol for Insulet is NASDAQ:PODD

Does Insulet pay dividends?

No, Insulet does not pay dividends

What sector is Insulet in?

Insulet is in the Healthcare sector

What industry is Insulet in?

Insulet is in the Medical Devices industry

What country is Insulet based in?

Insulet is headquartered in United States

When did Insulet go public?

Insulet's initial public offering (IPO) was on May 15, 2007

Is Insulet in the S&P 500?

Yes, Insulet is included in the S&P 500 index

Is Insulet in the NASDAQ 100?

No, Insulet is not included in the NASDAQ 100 index

Is Insulet in the Dow Jones?

No, Insulet is not included in the Dow Jones index

When was Insulet's last earnings report?

Insulet's most recent earnings report was on Feb 20, 2025

When does Insulet report earnings?

The next expected earnings date for Insulet is May 9, 2025

Should I buy Insulet stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions